Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 3Phase 1/2 2Phase NA 1

Status

Completed 2

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Head and Neck Neoplasms 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Interleukin-12 Subunit p35 × Clear all
NCT00004070 2017-04-20

Gene Therapy in Treating Patients With Unresectable, Recurrent, or Refractory Head and Neck Cancer

Dana-Farber Cancer Institute

Phase 1/2 Completed
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00002952 2013-09-05

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

University of Chicago

Phase 1/2 Completed
20 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡